A case report of using nivolumab for a malignant melanoma patient with rheumatoid arthritis

The use of antibodies against programmed cell death 1 (PD-1), which block inhibitory T cell checkpoints, is a promising new therapy for advanced malignant melanoma and NSCLC. However, patients with autoimmune diseases were excluded at the clinical trial using such immune checkpoint inhibitor, becaus...

Descripción completa

Detalles Bibliográficos
Autores principales: Kageyama, Shun-Ichiro, Yamaguchi, Shigeo, Ito, Shin, Suehara, Yoshiyuki, Saito, Tsuyoshi, Akaike, Keisuke, Miura, Kayo, Kato, Shunsuke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Japan 2016
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6498278/
https://www.ncbi.nlm.nih.gov/pubmed/31149453
http://dx.doi.org/10.1007/s13691-016-0256-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6498278/
https://www.ncbi.nlm.nih.gov/pubmed/31149453
http://dx.doi.org/10.1007/s13691-016-0256-8

Ejemplares similares